Allogene Therapeutics, Inc. (ALLO) — 8-K Filings

8-K Filings (16)

• Allogene Therapeutics Files 8-K — Apr 13, 2026 Risk: low
  Allogene Therapeutics, Inc. filed an 8-K on April 13, 2026, reporting other events. The filing does not contain specific financial figures or new material agree
• 8-K Filing — Apr 13, 2026
• Allogene Therapeutics Files 8-K for Other Event — Oct 14, 2025 Risk: medium
  Allogene Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an "Other Event" that occurred on September 26, 2025. The filing does not contain specif
• Allogene Therapeutics Files 8-K — Aug 1, 2025 Risk: low
  Allogene Therapeutics, Inc. filed an 8-K on August 1, 2025, reporting other events. The filing does not contain specific details about the nature of these event
• Allogene Therapeutics Files 8-K on Shareholder Vote & Exhibits — Jun 23, 2025 Risk: low
  On June 18, 2025, Allogene Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and e
• Allogene Therapeutics Enters Material Definitive Agreement — Feb 25, 2025 Risk: medium
  On February 19, 2025, Allogene Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement
• Allogene Therapeutics Announces Board and Compensation Changes — Jan 29, 2025 Risk: medium
  Allogene Therapeutics, Inc. announced on January 23, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Anthony J. Kim has be
• Pfizer to Acquire Allogene Therapeutics for $3.3 Billion — Nov 13, 2024 Risk: low
  Allogene Therapeutics, Inc. announced on November 11, 2024, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $3.3 billion in ca
• Allogene Therapeutics Files 8-K for Financials — Nov 7, 2024 Risk: low
  Allogene Therapeutics, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, and to file financial statements a
• Allogene Therapeutics Files 8-K for Ethics Code, Exhibits — Oct 7, 2024 Risk: low
  Allogene Therapeutics, Inc. filed an 8-K on October 7, 2024, reporting an amendment to its Code of Ethics and the filing of financial statements and exhibits. T
• Allogene Therapeutics Announces CMO Departure, Board Changes — Jun 10, 2024 Risk: medium
  Allogene Therapeutics, Inc. announced on June 5, 2024, the departure of Chief Medical Officer, Dr. Anthony Davies, and the appointment of Dr. Jessica Ng as inte
• Allogene Therapeutics Enters Material Definitive Agreement — May 31, 2024 Risk: medium
  Allogene Therapeutics, Inc. announced on May 24, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose the specific details o
• Allogene Therapeutics Files 8-K — May 14, 2024 Risk: low
  Allogene Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting an event that occurred on May 13, 2024. The filing indicates the company is providing inform
• Allogene Therapeutics Issues Non-Reliance on Past Financials — Feb 16, 2024 Risk: high
  Allogene Therapeutics, Inc. filed an 8-K on February 16, 2024, reporting that its previously issued financial statements for the fiscal years ended December 31,
• Allogene Therapeutics Enters Material Definitive Agreement — Jan 31, 2024
  Allogene Therapeutics, Inc. (ALLO) filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement" on January 25, 2024. This filing
• Allogene Therapeutics Reports Material Agreement, Exit Costs — Jan 5, 2024
  Allogene Therapeutics, Inc. filed an 8-K on January 5, 2024, reporting an event on January 3, 2024, related to entering a material definitive agreement and cost

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX